SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL is trending due to a significant stock drop following news that its NHS-Galleri cancer screening trial in the UK missed a primary endpoint, sparking intense debate between bears who see further downside and bulls who view the sell-off as an overreaction, pointing to strong financials and US market performance.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following a dual announcement: a $100 million non-dilutive royalty funding agreement and a simultaneous $100 million public offering. The community is sharply divided, with many expressing frustration over perceived dilution and management's choices, while others view the moves as strategic to unlock credit, secure financial runway, and strengthen the company's negotiating position for its pipeline assets.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending following recent positive comments from PepsiCo regarding its distribution partnership and Alani Nu integration, alongside a J.P. Morgan price target raise. The community is actively discussing the stock's growth potential and speculating on a possible PepsiCo acquisition, amidst ongoing concerns about stock price stability and management's communication leading into upcoming financial events.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending due to its recent earnings report, which highlighted strong revenue growth and significant investments for future expansion despite a net loss, coupled with a major patent extension until 2042 and the initiation of a new IBSRELA clinical trial, all fueling community speculation about a potential acquisition by Zydus Lifesciences.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending as its transformative all-stock acquisition of Valaris creates an offshore drilling powerhouse, driving community excitement for substantial synergies, a bolstered backlog, and potential for a significant re-rating ahead of its anticipated earnings report.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending following an earnings report that showcased robust revenue growth but also a net loss driven by increased credit loss provisions and an unclear path to profitability. This has polarized the community, with many calling the significant share price drop an overreaction to underlying growth, while others condemn the BNPL model as unsustainable amidst rising credit risks.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont Corp is trending following an earnings beat that surpassed revenue and EPS expectations, yet its stock performance is mixed as the community debates a more conservative 2026 production outlook. Despite strong financial results and a bullish sentiment around gold's record prices, investors are weighing future output guidance against the company's current performance and the broader precious metals rally.

AIOS Foundation

AIOS is trending following its recent ticker change from NISN, prompting renewed speculation among a divided community regarding its low float and potential as a "China penny play" amidst warnings of past dilution and upcoming offerings.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems Inc. is actively trending due to significant government contract activity, with awards totaling over $65 million for the P-8A Poseidon aircraft program, alongside new commercial robotics deals, fueling community discussions around its growth trajectory and potential for substantial future contracts in the expanding Edge AI and defense sectors.

Deere & Co. engages in the manufacture and distribution of equipment used in agriculture, construction, forestry, and turf care. It operates through the following segments: Agriculture and Turf, Construction and Forestry, and Financial Services. The Agriculture and Turf segment focuses on the distribution and manufacture of a full line of agriculture and turf equipment and related service parts. The Construction and Forestry segment offers machines and service parts used in construction, earthmoving, road building, material handling and timber harvesting. The Financial Services segment finances sales and leases by John Deere dealers of new and used agriculture and turf equipment and construction and forestry equipment. The company was founded by John Deere in 1837 and is headquartered in Moline, IL.

Deere & Co.

Deere & Co

Deere & Co is surging after reporting an earnings beat and raising its full-year guidance, with its CEO signaling the bottom of the agricultural cycle. While bulls are celebrating the strong price action and growth in construction and small agriculture, the community is actively debating if the stock is overbought given concerns about its valuation and broader declines in large farming equipment demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$WVE Eli Lilly is already investing in next-generation RNAi obesity treatments, while Novo Nordisk appears to be falling behind. 
 
OliX strikes $630 million deal with Lilly for obesity and liver disease drug 
Kim Ji-hye   Published 2025.02.10 
OliX Pharmaceuticals, a Korean biotech company specializing in RNA interference (RNAi) therapies, has signed an exclusive global licensing deal with Eli Lilly worth up to $630 million. 
… 
https://www.koreabiomed.com/news/articleView.html?idxno=26559

OliX Pharmaceuticals, a Korean biotech company specializing in RNA interference (RNAi) therapies, has signed an exclusive global licensing deal with Eli Lilly worth up to $630 million.The agreement, announced last Friday, grants Lilly the rights to develop and commercialize OLX75016, an experimental

OliX strikes $630 million deal with Lilly for obesity and liver disease drug

$WVE Lilly moves deeper into RNAi with $1.2B Sanegene obesity deal 
Nov. 11, 2025   By Tamra Sami 
In a deal worth $1.2 billion, Suzhou Sanegene Bio Inc. and Eli Lilly and Co. are partnering to advance RNAi candidates for metabolic diseases based on Sanegene&#39;s tissue selective delivery technology. (*) 
 
Genentech, SanegeneBio Launch Up-to-$1.7B RNAi Collaboration 
February 2, 2026 
Genentech, a member of the Roche Group, will apply SanegeneBio’s RNA interference (RNAi) platform to develop one of the company’s RNAi programs through a global licensing agreement that could generate up to $1.5 billion for the Chinese biotech.(**) 
 
(*) 
https://www.bioworld.com/articles/726150-lilly-moves-deeper-into-rnai-with-12b-sanegene-obesity-deal?v=preview 
(**) 
https://www.genengnews.com/topics/drug-discovery/genentech-sanegenebio-launch-up-to-1-7b-rnai-collaboration/

In a deal worth $1.2 billion, Suzhou Sanegene Bio Inc. and Eli Lilly and Co. are partnering to advance RNAi candidates for metabolic diseases based on Sanegene's tissue selective delivery technology.

Lilly moves deeper into RNAi with $1.2B Sanegene obesity deal

Under the agreement, SanegeneBio has granted Genentech exclusive worldwide rights to develop and commercialize the undisclosed program.

Genentech, SanegeneBio Launch Up-to-$1.7B RNAi Collaboration

StockTwits Web

Wave Life Sciences Ltd

Big Believer

 Eli Lilly is already investing in next-generation RNAi obesity treatments, while Novo Nordisk appears to be falling behind. 
 
OliX strikes $630 million deal with Lilly for obesity and liver disease drug 
Kim Ji-hye   Published 2025.02.10 
OliX Pharmaceuticals, a Korean biotech company specializing in RNA interference (RNAi) therapies, has signed an exclusive global licensing deal with Eli Lilly worth up to $630 million. 
… 
